Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

While the complete response letter derails a near-term clearance, one analyst described the rejection as more of “a speed ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...